Seres Therapeutics
Seres Therapeutics develops microbiome therapeutics, including the FDA-approved VOWST for recurrent C. difficile infection, and collaborates with Nestlé Health Science on certain programs.
Microbiome Therapeutics Development
Seres Therapeutics develops microbiome therapeutics aimed at transforming the lives of patients worldwide. The company's focus is on harnessing the human microbiome to create innovative treatments for a variety of serious conditions. Seres is actively working on therapeutic solutions intended to address diseases such as Clostridioides difficile infection, ulcerative colitis, and graft-versus-host disease, all of which have significant impacts on patient health and healthcare systems.
VOWST: FDA-Approved Microbiota-Based Therapeutic
Seres Therapeutics offers a product named VOWST, which is an FDA-approved microbiota-based therapeutic for the prevention of recurrent Clostridioides difficile infection in adults. This oral therapy represents a significant advancement in the treatment of C. difficile infection, a condition known to cause severe gastrointestinal issues and recurrence in many patients. VOWST showcases Seres Therapeutics' commitment to pioneering treatments that utilize the human microbiome to address previously hard-to-treat conditions.
Clinical Trials and Research Initiatives
Seres Therapeutics is engaged in conducting clinical trials for additional microbiome therapeutics. These trials target various conditions including C. difficile infection, ulcerative colitis, and graft-versus-host disease. Through these initiatives, the company is working to expand its portfolio of microbiome-based treatments and further validate the efficacy and safety of its therapeutic approaches. The clinical trials are a testament to Seres' dedication to advancing medical knowledge and offering new hope to patients.
Collaboration with Nestlé Health Science
Seres Therapeutics has established a collaboration with Nestlé Health Science to advance its C. difficile and inflammatory bowel disease (IBD) programs outside of North America. This partnership leverages Nestlé's global reach and expertise in health science to potentially extend the benefits of Seres' innovative therapeutics to a broader patient population. The collaboration focuses on the development and commercialization of treatments that address significant unmet needs in gastrointestinal health.
Research and Manufacturing Facilities
Seres Therapeutics operates research laboratories and manufacturing facilities located in Cambridge, Massachusetts. In addition to its Cambridge base, the company also maintains facilities in Irvine, California, and Tempe, Arizona. These locations are integral to the company's efforts in microbiome research and therapeutic development, supporting their mission through advanced research capabilities and production capacity. The strategic placement of these facilities enables efficient collaboration and innovation across multiple sites.
GoodNature Stool Donation Program
Seres Therapeutics runs a stool donation program named GoodNature, which is crucial to its microbiome therapeutic development efforts. The program involves the collection of high-quality stool samples from healthy donors, which are then used in the creation of investigational microbiome therapeutics. GoodNature not only plays a pivotal role in ensuring a reliable supply of material for research and production but also highlights the community-driven approach to advancing healthcare solutions.